SCHEMBL4160657

SCHEMBL4160657

CNS(=O)(=O)c1ccc2[nH]c(=O)c3[nH]cc(CCC(=O)O)c3c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.47
HTR5A P47898 1/20 0.47
HTR6 P50406 1/20 0.47
TAS2R14 Q9NYV8 1/20 0.45
KDM4E B2RXH2 5/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
GRIN3A Q8TCU5 1/20 0.41
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
PARP1 P09874 1/20 0.39
BAZ2B Q9UIF8 1/20 0.38
NQO2 P16083 1/20 0.37
MTNR1A P48039 1/20 0.37
GPR17 Q13304 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4155191 0.87 HPGD (0.42) KDM4EGRIN2DGRIN3BALDH1A1GRIN1
SCHEMBL4163279 0.87 PKM (0.48) HTR6PARP1POLBTDP1PKM
SCHEMBL4157628 0.87 ALDH1A1 (0.50) HTR6KDM4EALDH1A1HPGDPOLB
SCHEMBL4162915 0.86 PDGFRB (0.46) HPGDCYP2C19GPR17PDGFRBFGFR1
SCHEMBL4153573 0.86 PARG (0.52) KDM4EGRIN2DGRIN3BALDH1A1GRIN1
SCHEMBL4162942 0.86 KDM4E (0.44) HTR6KDM4EALDH1A1HPGDCYP2C19
SCHEMBL4153950 0.85 PKM (0.50) KDM4EGRIN2DGRIN3BALDH1A1GRIN1
SCHEMBL4166095 0.85 TDP1 (0.51) TAS2R14KDM4EALDH1A1CYP2C19POLB
SCHEMBL4161137 0.85 POLB (0.50) HTR6ALDH1A1POLBTDP1MEN1
SCHEMBL4167129 0.85 POLB (0.41) KDM4EGRIN2DGRIN3BALDH1A1GRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 HTR7 3935/4885HTR5A 4215/4885HTR6 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.